Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Meiotic double-stranded break formation protein 4 (MEI4) is an evolutionarily conserved protein essential for the initiation of programmed DNA double-strand breaks (DSBs) during early meiotic prophase, a pivotal step for homologous recombination and chromosome segregation in meiosis[1][2][3]. MEI4 is required for the correct localization and activation of the SPO11 complex, which catalyzes DSB formation[1][2]. MEI4 localizes as discrete foci on meiotic chromosome axes and interacts directly with REC114, forming part of the conserved machinery necessary for DSB formation[2][4]. Loss of MEI4 in model organisms like mice leads to complete infertility due to the absence of meiotic DSBs[2]. There are no known drug interactions or current direct therapeutic applications, and MEI4 is not considered a therapeutic target, but it plays a fundamental biological role in gametogenesis and genetic diversity[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Meiotic double-stranded break formation protein 4 (MEI4).